ID: h-SDA-2026-04-26-gap-debate-20260417-033
Hypothesis
CSF p-tau217 Normalization Occurs Earlier Than Amyloid PET Negativity, Enabling Earlier Cessation Decisions
CSF p-tau217 normalizes before amyloid PET reaches cessation thresholds because p-tau217 reflects active neuronal pathology while amyloid PET measures accumulated plaques.
neurodegeneration
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 5 support✗ 4 oppose
✓ All Quality Gates Passed
🧪 Overview
CSF p-tau217 normalizes before amyloid PET reaches cessation thresholds because p-tau217 reflects active neuronal pathology while amyloid PET measures accumulated plaques. This temporal disconnect means p-tau217 normalization may identify the critical window when ongoing amyloid-driven neurodegeneration has ceased, potentially allowing treatment cessation before complete amyloid clearance. The faster decline kinetics of p-tau217 compared to amyloid PET offer practical clinical utility for reducing ARIA risk, treatment burden, and cost.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Active Neuronal<br/>Pathology"]
B["CSF p-tau217<br/>Elevation"]
C["Amyloid PET<br/>Accumulates"]
D["PET Cessation<br/>Threshold"]
E["p-tau217<br/>Normalization"]
F["Earlier Cessation<br/>Decision"]
A --> B
A --> C
C --> D
B --> E
E --> F
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style B fill:#e65100,stroke:#ffab91,color:#ffab91
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports4 contradicts
Supports
Plasma p-tau217 shows faster decline kinetics compared to amyloid PET post-treatment
Supports
Tau biomarkers demonstrate greater treatment responsiveness than static amyloid measures
Supports
Phosphorylated tau species decline more rapidly than total tau following intervention
Supports
CSF p-tau217 showed treatment effects at 24 weeks before amyloid PET effects plateaued
Supports
FDA has accepted biomarker-based endpoints for drug approval (Aduhelm accelerated approval based on amyloid PET)
Contradicts
Observed kinetic differential may reflect assay-specific pharmacodynamics rather than biological process differences
Contradicts
If baseline p-tau217 levels cluster near assay detection limits, apparent normalization may be measurement artifact
Contradicts
Biomarker normalization in trials rarely translates to functional recovery, suggesting critical window concept may be oversimplified
Contradicts
Plasma p-tau217 declines plateau in some patients, suggesting not all pathology is equally reversible
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — N
No curated PDB or AlphaFold mapping for N yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for N.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0563
Events (7d)
1
Price History
▼2.3%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF participants receiving anti-amyloid immunotherapy (lecanemab, donanemab, or aducanumab) are monitored with concurrent CSF p-tau217 and amyloid PET measurements at 3-month intervals for 36 months, T | Median time to CSF p-tau217 normalization will be at least 6 months shorter than median time to amyloid PET negativity, with >70% of participants showing this t | — no observation — | pending | 0.65 |
| IF participants who achieve CSF p-tau217 normalization are randomized to immediate treatment cessation versus continued treatment for 24 additional months, THEN the immediate cessation group will demo | Immediate cessation group based on p-tau217 normalization shows mean 12-month CDR-SB change ≤0.5 points worse than continued treatment group, confirming identif | — no observation — | pending | 0.45 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF participants receiving anti-amyloid immunotherapy (lecanemab, donanemab, or aducanumab) are monitored with concurrent CSF p-tau217 and amyloid PET measurements at 3-month intervals for 36 months, THEN CSF p-tau217 will normalize to the 90th percentile of cognitively normal controls before amyloid
Predicted outcome: Median time to CSF p-tau217 normalization will be at least 6 months shorter than median time to amyloid PET negativity, with >70% of participants show
Falsification: Amyloid PET reaches negativity thresholds before CSF p-tau217 normalization in ≥50% of participants, disproving the stated faster decline kinetics of p-tau217.
pendingconf 45%
IF participants who achieve CSF p-tau217 normalization are randomized to immediate treatment cessation versus continued treatment for 24 additional months, THEN the immediate cessation group will demonstrate non-inferior clinical outcomes measured by 12-month change in CDR-SB (margin: 0.5 points) co
Predicted outcome: Immediate cessation group based on p-tau217 normalization shows mean 12-month CDR-SB change ≤0.5 points worse than continued treatment group, confirmi
Falsification: Immediate cessation group shows clinically meaningful decline defined as 12-month CDR-SB increase ≥1.5 points or conversion to dementia in ≥20% of participants, indicating premature cessation before n
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.